Tocilizumab can boost catch-up growth in systemic JIA

11/14/2012 | Family Practice News

Tocilizumab, an interleukin-6 receptor inhibitor marketed as Actemra, significantly increased the height velocities of most patients with systemic juvenile idiopathic arthritis, according to a study presented at the American College of Rheumatology meeting. Higher insulinlike growth factor-1 levels and osteocalcin/C-telopeptide of type 1 collagen ratios linked to the use of the drug suggests the treatment can benefit growth hormone axis and bone metabolism, researchers said.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX